Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, Avnish, Yao, Wantong, Ying, Haoqiang, Hua, Sujun, Liewen, Alison, Wang, Qiuyun, Zhong, Yi, Wu, Chang-Jiun +22 more·2014·Cell
DOI 10.1016/j.cell.2014.06.003

Cited by (717)

Items 401–500 of 717

  1. GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models
    Debora Stelitano, Yamila Peche Leticia, Emiliano Dalla, Martín Monte, Silvano Piazza, Claudio Schneider · 2017 · Oncotarget
  2. Knockdown of anion exchanger 2 suppressed the growth of ovarian cancer cells via mTOR/p70S6K1 signaling
    Li-Jun Zhang, Renquan Lu, Ya-Nan Song, Jian‐Yong Zhu, Wei Xia, Miao Zhang, Zhi-Yi Shao, Yan Huang, Yuqi Zhou, Hongqin Zhang et al. · 2017 · Scientific Reports
  3. Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells
    Yongqing Liu, Laura Siles, Xiaoqin Lu, Kevin C. Dean, Míriam Cuatrecasas, Antonio A. Postigo, Douglas C. Dean · 2018 · Nature Communications
  4. The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and Cancer
    Greg Malnassy, Leah M. Ziolkowski, Kay F. Macleod, Scott A. Oakes · 2024 · Gastroenterology
  5. NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer
    Daiyong Deng, Habeebunnisa Begum, Tong Liu, Jiangyan Zhang, Qiang Zhang, Tingyu Chu, Hong Li A, Alexander D. Lemenze, Mainul Hoque, Patricia Soteropoulos et al. · 2024 · The Journal of Experimental Medicine
  6. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells
    Yang Li, Shanshan Yang, Nouara C. Sadaoui, Wei Ming Hu, Santosh K. Dasari, Lingegowda Selanere Mangala, Yunjie Sun, Shuangtao Zhao, Linghua Wang, Yuan Liu et al. · 2020 · iScience
  7. Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal
    Chai, Tin Fan, Manu, Kanjoormana Aryan, Casey, Patrick J., Wang, Mei · 2020 · Oncogene
  8. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma
    Hiroki Tamagawa, Masayuki Fujii, Kazuhiro Togasaki, Takashi Seino, Shintaro Kawasaki, Ai Takano, Kohta Toshimitsu, Sirirat Takahashi, Yuki Ohta, Mami Matano et al. · 2024 · Nature Cell Biology
  9. The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients’ Survival
    Janusz Godlewski, Jacek Kieżun, Bartłomiej E. Kraziński, Zygmunt Kozielec, Piotr Wierzbicki, Zbigniew Kmieć · 2018 · BioMed Research International
  10. An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases
    Di Chen, Zhen Ning, Huan Chen, Chang Lu, Xiaolong Liu, Tian Xia, Huan Qi, Wen Wang, Ting Ling, Xin Guo et al. · 2019 · Oncogene
  11. Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
    Daniel Heudobler, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Christopher Gerner, Pan Pantziarka, Lina Ghibelli, Albrecht Reichle · 2019 · Frontiers in Oncology
  12. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma
    Honghai Dai, Yang Washington Shao, Xiaoling Tong, Xue Wu, Jiaohui Pang, Alei Feng, Zhe Yang · 2019 · Cancer Medicine
  13. Independent and core pathways in oncogenic KRAS signaling
    Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang · 2016 · Expert Review of Proteomics
  14. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket
    Jongwan Kim, Haiyan Jin, J S Kim, Seon Yeon Cho, Sungho Moon, Jianmin Wang, Jiashun Mao, Kyoung Tai No · 2024 · International Journal of Molecular Sciences
  15. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis
    Mi‐Ju Kim, Seav Huong Ly, Yingtian Xie, Gina N. Duronio, Dane Ford-Roshon, Justin H. Hwang, Rita Sulahian, Jonathan P. Rennhack, Jonathan So, Ole V. Gjoerup et al. · 2022 · Developmental Cell
  16. Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer
    Kimberly C. Lin, Hyun Woo Park, Kun‐Liang Guan · 2017 · Annual Review of Cancer Biology
  17. RNA binding proteins: Linking mechanotransduction and tumor metastasis
    Yunqiu Zhang, Zhonghan Li · 2020 · Cancer Letters
  18. Hippo Signaling Pathway in Pancreas Development
    Yifan Wu, Pauline Aegerter, MICHAEL J. NIPPER, Logan R Ramjit, Jun Liu, Pei Wang · 2021 · Frontiers in Cell and Developmental Biology
  19. Augmentation of the therapeutic efficacy of WEE 1 kinase inhibitor AZD 1775 by inhibiting the YAP –E2F1– DNA damage response pathway axis
    Yusuke Oku, Naoyuki Nishiya, Takaaki Tazawa, Takaya Kobayashi, Nanami Umezawa, Yasuyo Sugawara, Yoshimasa Uehara · 2018 · FEBS Open Bio
  20. Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance
    Xintong Zhang, Yaru Du, Axel Behrens, Linxiang Lan · 2025 · Developmental Cell
  21. Chinese Propolis Suppressed Pancreatic Cancer Panc-1 Cells Proliferation and Migration via Hippo-YAP Pathway
    Lingchen Tao, Xi Chen, Yufei Zheng, Yuqi Wu, Xiasen Jiang, Mengmeng You, Shanshan Li, Fuliang Hu · 2021 · Molecules
  22. Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer
    Ting Sun, Hui Peng, Wenhao Mao, Liwei Ma, Hongyang Liu, Jia Mai, Lin Jiao · 2021 · International Journal of Biological Sciences
  23. A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis
    Jiacheng He, Xian-Hua Lin, Fanhui Meng, Yumiao Zhao, Wei Wang, Yao Zhang, Xiaolei Chai, Ying Zhang, Weiwei Yu, Junjie Yang et al. · 2022 · Molecules
  24. BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis
    Wei‐Ming Wang, Xiang Zhou, Lingming Kong, Zhenyan Pan, Gang Chen · 2024 · Cancers
  25. Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer
    Kanchan Singh, Melissa A. Pruski, Kishore Polireddy, Neal C. Jones, Qingzheng Chen, Jun Yao, Wasim A. Dar, Florencia M. McAllister, Cynthia Ju, Holger K. Eltzschig et al. · 2019 · Oncogene
  26. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
    Keith Graham, Philip Lienau, Benjamin Bader, Stefan Prechtl, Jan Naujoks, Ralf Lesche, Joerg Weiske, Julia Kuehnlenz, Krzysztof Brzezinka, Lisette Potze et al. · 2024 · Cell chemical biology
  27. Alternative Splicing in the Hippo Pathway—Implications for Disease and Potential Therapeutic Targets
    Sean R. Porazinski, Michael Ladomery · 2018 · Genes
  28. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654
    Chenxi Gao, Guangming Chen, Dennis Han Zhang, Judy Zhang, Shih–Fan Kuan, Wenhuo Hu, Farzad Esni, Xuan Gao, Jun‐Lin Guan, Edward Chu et al. · 2019 · Cellular and Molecular Gastroenterology and Hepatology
  29. Lessons from expanded potential of embryonic stem cells: Moving toward totipotency
    Rongrong Le, Yixin Huang, Anqi Zhao, Shaorong Gao · 2020 · Journal of genetics and genomics/Journal of Genetics and Genomics
  30. p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth
    Hanyue Ouyang, Phi Luong, Morten Frödin, Steen H. Hansen · 2020 · Oncogene
  31. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
    Tadashi Manabe, Trever G. Bivona · 2022 · Journal of Clinical Investigation
  32. “Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines”
    Luca Sanna, Roberta Piredda, Irene Marchesi, Valentina Bordoni, Sonia Vanina Forcales, Diego Francesco Calvisi, Luigi Bagella · 2019 · Chemico-Biological Interactions
  33. The mechanism of YAP/TAZ transactivation and dual targeting for cancer therapy
    Man Yu, Jingning Wang, Xiao Zhang, Haoran Zhang, Chaoqiang Li, Juebei Li, Jiaming Lin, Jie Zheng, Liu Huang, Yan Li et al. · 2025 · Nature Communications
  34. Spatial hepatocyte plasticity of gluconeogenesis during the metabolic transitions between fed, fasted and starvation states
    Junichi Okada, Austin Landgraf, Alus M. Xiaoli, Li Ping Liu, Maxwell Horton, Victor L. Schuster, Fajun Yang, Simone Sidoli, Yunping Qiu, Irwin J. Kurland et al. · 2025 · Nature Metabolism
  35. CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
    Daoyan Wei, Liang Wang, Yi Liu, Xiangsheng Zuo, Xiling Shen, Robert S. Bresalier · 2025 · Clinical Cancer Research
  36. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
    Kathleen M. McAndrews, Francesca Paradiso, Clint A. Stalnecker, Benson Chellakkan Selvanesan, Fredrik I. Thege, David H. Peng, Barbara A. Moreno Diaz, Hikaru Sugimoto, Sarah I. Patel, Krishnan K. Mahadevan et al. · 2025 · Science Translational Medicine
  37. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
    Samantha Z. Brown, Grace A. McCarthy, James R. Carroll, Roberto Di Niro, Carl Pelz, Aditi Jain, Thomas Lee Sutton, Hannah D. Holly, Avinoam Nevler, Christopher William Schultz et al. · 2022 · Molecular and Cellular Biology
  38. Conquering oncogenic KRAS and its bypass mechanisms
    Pingping Hou, Yanru Wang · 2022 · Theranostics
  39. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer
    Hye-Been Yoo, Jin Woo Moon, Hwa-Ryeon Kim, Hee Seung Lee, Koji Miyabayashi, Chan Hee Park, Sabrina Ge, Amy Xin Wei Zhang, Yoo Keung Tae, Yujin Sub et al. · 2023 · Gastroenterology
  40. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
    Hsiao-Ching Chuang, Po-Hsien Huang, Samuel Kiyota Kulp, Ching‐Shih Chen · 2017 · Pharmacological Research
  41. Role and regulation of Yap in KrasG12D-induced lung cancer
    Yaopan Mao, Shuguo Sun, Kenneth D. Irvine · 2017 · Oncotarget
  42. Viral Manipulation of a Mechanoresponsive Signaling Axis Disassembles Processing Bodies
    Elizabeth L. Castle, Carolyn-Ann Robinson, Pauline Douglas, Kristina D. Rinker, Jennifer A. Corcoran · 2021 · Molecular and Cellular Biology
  43. Functions of Yes-association protein (YAP) in cancer progression and anticancer therapy resistance
    Yu Zhang, Xiang Wang, Xiuping Zhou · 2022 · Brain Science Advances
  44. Down‐regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor
    Yangyang Yao, Yi Wang, Li Li, Xiaojun Xiang, Junhe Li, Jun Chen, Zhen Liu, Shanshan Huang, Jianping Xiong, Jun Deng · 2019 · Journal of Cellular and Molecular Medicine
  45. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis
    Xiaoyan Lu, Quan Gan, Caibin Gan, Yunpeng Zheng, Bingjie Cai, Xuyang Li, Dongqin Li, Guangwen Yin · 2020 · Life Sciences
  46. Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis
    Jinhe Yang, Junli Wang, Hongmei Zhang, Chang Long Li, Changyan Chen, Tongbo Zhu · 2020 · Carcinogenesis
  47. RAS GTPase signalling to alternative effector pathways
    Swati Singh, Matthew James Smith · 2020 · Biochemical Society Transactions
  48. Models of pancreatic ductal adenocarcinoma
    Rayane Dennaoui, Hridaya Shrestha, Kay-Uwe Wagner · 2021 · Cancer Metastasis Review
  49. One-shot dual gene editing for drug-resistant pancreatic cancer therapy
    Eun-Jeong Won, Hyeji Park, Seung-Hee Chang, Jin Hyun Kim, Hojeong Kwon, Young‐Seok Cho, Tae‐Jong Yoon · 2021 · Biomaterials
  50. Capicua Suppresses YAP1 To Limit Tumorigenesis and Maintain Drug Sensitivity in Human Cancer
    Ji Won Kim, Cuyler Luck, Wei Wu, Rovingaile Kriska Ponce, Yone Kawe Lin, Nehal Gupta, Ross A. Okimoto · 2021 · Cell Reports
  51. Untitled work
    2023 · PubMed Central
  52. Low angiomotin‐p130 with concomitant high Yes‐associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer
    Soon Auck Hong, Myoung Won Son, Junhun Cho, Si‐Hyong Jang, Hyun Ju Lee, Ji‐Hye Lee, Hyun Deuk Cho, Mee‐Hye Oh, Moon Soo Lee · 2017 · Apmis
  53. Mu‐KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer
    Peipei Wang, Hongmei Zhang, Jinhe Yang, Zongxian Li, Yiren Wang, Xiaohong Leng, Suthakar Ganapathy, Pauline Isakson, Changyan Chen, Tongbo Zhu · 2019 · Journal of Cellular Physiology
  54. <scp>KRAS</scp> inhibitors: going noncovalent
    Drosten, Matthias, Barbacid, Mariano · 2022 · Molecular Oncology
  55. Targeting the Hippo/YAP Pathway: A Promising Approach for Cancer Therapy and Beyond
    Rajni Bala, Reecha Madaan, Onkar Bedi, Amrinder Singh, Ayushi Taneja, Renu Dwivedi, Gabriela Figueroa‐González, Octavio Daniel Reyes‐Hernández, Laura Itzel Quintas Granados, Hernán Cortés et al. · 2025 · MedComm
  56. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
    James W. Sinnett‐Smith, Tarique Anwar, Elaine F. Reed, Yaroslav Teper, Guido Eibl, Enrique Rozengurt · 2022 · Molecular Cancer Therapeutics
  57. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
    Linette, Gerald P., Bear, Adham S., Carreno, Beatriz M. · 2024 · Clinical Cancer Research
  58. Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer
    Clare Sheridan, Julian Downward · 2015 · Current Protocols in Pharmacology
  59. Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study
    Jin Zhang, Xuesong Li, Yi Lu, Guowen Wang, Ying Ma · 2023 · Cancers
  60. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
    Ashton Anthony Connor, Steve Gallinger · 2017 · Expert Review of Gastroenterology & Hepatology
  61. Targeting YAP Degradation by a Novel 1,2,4-Oxadiazole Derivative via Restoration of the Function of the Hippo Pathway
    Eman M.E. Dokla, Chunsheng Fang, Po‐Chen Chu, Chih‐Shiang Chang, Khaled A. M. Abouzid, C. S. Chen · 2020 · ACS Medicinal Chemistry Letters
  62. YAP/TAZ enhances P-body formation to promote tumorigenesis
    Xia Shen, Xiang Peng, Yuegui Guo, Zhujiang Dai, Long Cui, Wei Yu, Yun Liu, Chen‐Ying Liu · 2023 · eLife
  63. Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma
    John G. Yuen, Ga‐Ram Hwang, Andrew T. Fesler, Erick Intriago, A.S. Pal, Anushka Ojha, Jingfang Ju · 2024 · Molecular Therapy Oncology
  64. Injury promotes sarcoma development in a genetically and temporally restricted manner
    David Van Mater, Eric S. Xu, Anupama Reddy, Leonor Añó, Mohit Sachdeva, Wesley Huang, Nerissa T. Williams, Yan Ma, Cassandra Love, Lanie E. Happ et al. · 2018 · JCI Insight
  65. MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition
    Nina Therese Solberg, Maria Melheim, Martin Frank Strand, Petter Angell Olsen, Stefan Johannes Karl Krauss · 2019 · Cancers
  66. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
    Dietrich Alexander Ruess, Kıvanç Görgülü, Sonja M. Wörmann, Hana Algül · 2017 · Drugs & Aging
  67. Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma
    Lu Shi, Shanshan Zhou, Wan-Bo Chen, Lei Xu · 2017 · Experimental and Therapeutic Medicine · Retracted
  68. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
    M. Alhothali, Mevin Mathew, Geeta Iyer, H. Lawrence, Sheng-Yu Yang, S. Chellappan, J. Padmanabhan · 2019 · International Journal of Molecular Sciences
  69. Sequestration of Intestinal Acidic Toxins by Cationic Resin Attenuates Pancreatic Cancer Progression through Promoting Autophagic Flux for YAP Degradation
    Guangfu Zhao, Tianci Zhang, Wei Chiang Liu, Mouad Edderkaoui, Richard Hu, Jun Li, Stephen Jacob Pandol, Xiangsheng Fu, Yuan‐Ping Han · 2022 · Cancers
  70. Complex interplay between RAS GTPases and RASSF effectors regulates subcellular localization of YAP
    Swati Singh, Gabriela Bernal Astrain, Ana Maria Hincapie, Marilyn Goudreault, Matthew James Smith · 2024 · EMBO Reports
  71. PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
    Peipei Wang, Dapeng Wei, Hongmei Zhang, Jiao Chen, Dingding Zhang, Suthakar Ganapathy, Pauline Isakson, Changyan Chen, Tongbo Zhu · 2018 · Oncotarget
  72. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Hitomi Kawai, Ryouta Matsuoka, Takeshi Ito, Daisuke Matsubara · 2022 · Frontiers in Bioscience-Landmark
  73. miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review)
    Taruna Katyal Arora, Mohd Adnan Kausar, Shimaa M. H. Aboelnaga, Sadaf Anwar, Malik Hussain, Sadaf Sadaf, Simran Kaur, Alaa Abdulaziz Eisa, Vyas Shingatgeri, Mohammad Zeeshan Najm et al. · 2022 · Oncology Reports
  74. Heptadecanoic Acid, an Odd-Chain Fatty Acid, Induces Apoptosis and Enhances Gemcitabine Chemosensitivity in Pancreatic Cancer Cells
    Hee Young Kim, Jeong Yong Moon, Somi Kim Cho · 2023 · Journal of Medicinal Food
  75. All eyes on YAP1
    Sarah E. Seton-Rogers · 2014 · Nature reviews. Cancer
  76. MicroRNA-186 affects the proliferation of tumor cells via yes-associated protein 1 in the occurrence and development of pancreatic cancer
    Qinghui Niu, Xiaoyu Li, Di Xia, Yueping Jiang, Zibin Tian, Cheng Bian, Cuiping Zhang, Pei Liu, Fengjuan Zhang, Yuling Yang et al. · 2017 · Experimental and Therapeutic Medicine
  77. Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer
    Chao Gao, Meiyu Quan, Qianjie Chen, Ruo Yang, Yuanyuan Wu, Jiayu Liu, Zhongyuan Lin, Xue Li, Jueting Cai, Tian‐Fang Jiang et al. · 2021 · Frontiers in Oncology
  78. The Hippo pathway: a renewed insight in the craniofacial diseases and hard tissue remodeling
    Jun Chen, Jingyi Cheng, Cong Zhao, Boxuan Zhao, Jia Mi, Wenjie Li · 2021 · International Journal of Biological Sciences
  79. Yorkie-Cactus (IκBα)-JNK axis promotes tumor growth and progression in Drosophila
    Snigdha, Kirti, Singh, Amit, Kango-Singh, Madhuri · 2021 · Oncogene
  80. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
    Oh, Hwanhee, Hwang, Inah, Jang, Ja-Young, Wu, Lingxiang, Cao, Dongqing, Yao, Jun, Ying, Haoqiang, Li, Jian Yi, Yao, Yu, Hu, Baoli et al. · 2021 · Cancer Research
  81. Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications
    Yuuki Ohara, Huaitian Liu, Paloma Moreno, Seiya Suzuki, S. Perwez Hussain · 2025 · Pharmacology & Therapeutics
  82. A Novel PHD2/VHL-mediated Regulation of YAP1 Contributes to VEGF Expression and Angiogenesis
    Namrata Bora-Singhal, Biswarup Saha, Durairaj Mohankumar, Jaya Padmanabhan, Domenico Coppola, Srikumar Chellappan · 2022 · Cancer Research Communications
  83. YAP/TAZ interacts with RBM39 to confer resistance against indisulam
    Toshinori Ando, Kento Okamoto, Yume Ueda, Nanako Kataoka, Tomoaki Shintani, Souichi Yanamoto, Mutsumi Miyauchi, Mikihito Kajiya · 2024 · Oncogenesis
  84. The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
    Bing Zhong, Jintao Du, Feng Liu, Silu Sun · 2025 · MedComm
  85. The Hippo pathway: an emerging role in urologic cancers.
    Bekir Cinar, Esma Alp, Marwah M. Al‐Mathkour, Ava Millicent Boston, Abdulrahman M. Dwead, Kezhan Khazaw, Alexis Gregory · 2021 · Europe PMC (PubMed Central)
  86. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule
    Bashir Lawal, Alexander T.H. Wu, Hsu‐Shan Huang · 2022 · Frontiers in Immunology
  87. PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism
    Yoshinori Matsumoto, Robert K. Rottapel · 2023 · Trends in Molecular Medicine
  88. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
    Timothy R. Donahue, David W. Dawson · 2016 · Trends in Endocrinology and Metabolism
  89. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia
    Emily J. Pomeroy, Lindsey A. Lee, R D W Lee, Dawn K. Schirm, Nuri A. Temiz, Jing Ma, Tanja Andrea Gruber, Ernesto Díaz-Flores, Branden S. Moriarity, James R. Downing et al. · 2016 · Oncogene
  90. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation
    Yusuke Oku, Naoyuki Nishiya, S. Sugiyama, Haruka Sato, Yoshimasa Uehara · 2018 · Anticancer Research
  91. YAP confers resistance to vandetanib in medullary thyroid cancer
    Huan Wang, Jian Tang, Zhiwei Su · 2020 · Biochemistry and Cell Biology
  92. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers
    Carla Mottini, Luca Cardone · 2020 · International Journal of Molecular Sciences
  93. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis
    Ce Li, Zhenzi Peng, Yizhou Wang, Gloria Lam, Nicholas N. Nissen, Jie Tang, Xiaopu Yuan, Michael S. Lewis, Mark Irwin Greene, Stephen Jacob Pandol et al. · 2021 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  94. Mouse Models of Pancreatic Ductal Adenocarcinoma
    Mariano Ponz‐Sarvisé, David Arthur Tuveson, Kenneth H. Yu · 2015 · Hematology/Oncology Clinics of North America
  95. TSG-6–Mediated Extracellular Matrix Modifications Regulate Hypoxic–Ischemic Brain Injury
    Taasin Srivastava, Hung Nguyen, Gage Haden, Parham Diba, Steven W. Sowa, Norah LaNguyen, William Reed-Dustin, Wenbin Zhu, Xi Gong, Edward N. Harris et al. · 2024 · Journal of Neuroscience
  96. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy
    Kritisha Bhandari, Wei‐Qun Ding · 2024 · International Journal of Molecular Sciences
  97. YAP promotes global mRNA translation to fuel oncogenic growth despite starvation
    Daehee Hwang, Seonguk Baek, Jeeyoon Chang, Taejun Seol, Bomin Ku, Hongseok Ha, Hyeonji Lee, Suhyeon Cho, Tae‐Young Roh, Yoon Ki Kim et al. · 2024 · Experimental & Molecular Medicine
  98. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer
    Yohei Saito, Yi Qun Xiao, Jun Yao, Yunhai Li, Wendao Liu, Arseniy E. Yuzhalin, Yueh-Ming Shyu, Hongzhong Li, Xiangliang Yuan, Ping Li et al. · 2024 · Cell Discovery
  99. YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells
    Rahil Noorizadeh, Barbara Sax, Tahereh Javaheri, Branka Radic-Sarikas, Valerie Fock, Veveeyan Suresh, Maximilian O. Kauer, Aleksandr Bykov, Danijela Kurija, Michaela Schlederer et al. · 2025 · Cell Reports
  100. PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
    Kazuya Matsumoto, Yoshinori Matsumoto, Jun Wada · 2025 · Frontiers in Immunology